Overview

Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years

Status:
Completed
Trial end date:
2010-08-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of recombinant human growth hormone (r-hGH) treatment in girls with Turner Syndrome under the age of 4 years. After 4 years of treatment, height in these girls will be compared with an historical control group of untreated girls with Turner Syndrome, matched for age and height at baseline.
Phase:
Phase 4
Details
Lead Sponsor:
Merck KGaA, Darmstadt, Germany
Treatments:
Hormones